Here is the design of a clinical trial:

Official Title: Malaria Chemoprevention With Monthly Treatment With Dihydroartemisinin-Piperaquine for the Post-discharge Management of Severe Anaemia in Children Less Than 5 Years in Malawi

Included conditions:
- Malaria
- Severe Anemia

Study Armgroups:
- {'label': 'Drug + short message(SMS) reminder', 'type': 'OTHER', 'description': 'dihydroartemesinin-piperaquine (3-day treatment courses, given 2, 6, and 10 weeks after enrolment) with SMS reminders prior to each treatment course', 'interventionNames': ['Drug: dihydroartemisinin-piperaquine', 'Other: short message(SMS) reminder']}
- {'label': 'Drug + no short message(SMS) reminder', 'type': 'OTHER', 'description': 'dihydroartemisinin-piperaquine (3-day treatment courses, given 2, 6, and 10 weeks after enrolment) without SMS reminders prior to each treatment course.', 'interventionNames': ['Drug: dihydroartemisinin-piperaquine']}
- {'label': 'Drug+ Health worker reminder', 'type': 'OTHER', 'description': 'dihydroartemisinin-piperaquine (3-day treatment courses, given 2, 6, and 10 weeks after enrolment) with Health surveillance assistants reminders prior to each treatment course.', 'interventionNames': ['Drug: dihydroartemisinin-piperaquine', 'Other: Health worker reminder']}
- {'label': 'Drug at hospital + SMS reminder', 'type': 'OTHER', 'description': 'dihydroartemisinin-piperaquine (3-day treatment courses, given 2, 6, and 10 weeks after enrolment) collected at the outpatient department without an SMS reminders prior to each treatment course.', 'interventionNames': ['Drug: dihydroartemisinin-piperaquine']}
- {'label': 'Drug at Hospital+no SMS reminder', 'type': 'OTHER', 'description': 'dihydroartemisinin-piperaquine (3-day treatment courses, given 2, 6, and 10 weeks after enrolment) collected at the outpatient department with a short message reminder prior to each treatment course', 'interventionNames': ['Drug: dihydroartemisinin-piperaquine', 'Other: message(SMS) reminder']}

Interventions:
- {'type': 'DRUG', 'name': 'dihydroartemisinin-piperaquine', 'armGroupLabels': ['Drug + no short message(SMS) reminder', 'Drug + short message(SMS) reminder', 'Drug at Hospital+no SMS reminder', 'Drug at hospital + SMS reminder', 'Drug+ Health worker reminder']}
- {'type': 'OTHER', 'name': 'message(SMS) reminder', 'armGroupLabels': ['Drug at Hospital+no SMS reminder']}
- {'type': 'OTHER', 'name': 'Health worker reminder', 'description': 'Health surveillance assistants reminders prior to each treatment course', 'armGroupLabels': ['Drug+ Health worker reminder']}
- {'type': 'OTHER', 'name': 'short message(SMS) reminder', 'armGroupLabels': ['Drug + short message(SMS) reminder']}

Primary Outcomes:
- {'measure': 'Proportion of those with 100 % uptake of PMC drugs during the 15 weeks of the study period.', 'description': '100 % uptake is defined as administration of all study drugs and compliance to study visits during the course of 15 weeks.', 'timeFrame': '15 weeks'}

Please estimate the sample size based on the assumption: 
ICC of 0.1, 10% loss-to-follow-up, 80% power, significance level (α) of 0.05
Sample size
        The sample size calculation has been adjusted for the design effect using the coefficient of variation method in order to account for the Intra-cluster Correlations (ICC) [15, 16]. We assumed that the cluster sizes would be uniformly distributed between 2 and 4 children [2, 4]. This gives a mean cluster size of 3 children per village per year and a standard deviation of cluster sizes of 0.58. Hence the coefficient of variation of cluster sizes (CV) is 0.58/3â=â0.19 and CV2Â =â0.036. Assuming an intra-cluster correlation coefficient (ICC) of 0.1 and allowing for 10% loss-to-follow-up, a sample size of 25 clusters (villages) of an average of 3 children per village (75 children per arm, Nâ=â375 overall (for 125 clusters for the 5 arms)) has 80% power to detect a 25% absolute increase in uptake from an estimated 50% in the OPD and delivery at home groups to 75% in the arms supported by SMS reminders (Î±â=â0.05). The ICC of 0.1 is slightly more conservative than the ICC in a previous trial of delivery approaches for IPTc in the Gambia.